Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | SOD1 | P00441 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL27492762 | 0.95 | NR4A2 (0.58) | MAOBNR4A2NR4A1NR4A3SOD1 | |
| SCHEMBL13439843 | 0.91 | NR4A2 (0.57) | MAOBNR4A2NR4A1NR4A3SOD1 | |
| SCHEMBL10474017 | 0.88 | MAOB (0.60) | MAOBNR4A2NR4A1NR4A3BCHE | |
| SCHEMBL15650460 | 0.87 | MAOB (0.58) | MAOBNR4A2NR4A1NR4A3BCHE | |
| SCHEMBL9434943 | 0.87 | MAOB (0.58) | MAOBNR4A2NR4A1NR4A3BCHE | |
| SCHEMBL13761594 | 0.87 | NR4A2 (0.56) | MAOBNR4A2NR4A1NR4A3SOD1 | |
| SCHEMBL10472144 | 0.87 | MAOB (0.58) | MAOBNR4A2NR4A1NR4A3BCHE | |
| SCHEMBL20098899 | 0.86 | MAOB (0.56) | MAOBNR4A2NR4A1NR4A3BCHE | |
| SCHEMBL13439834 | 0.85 | NPC1 (0.58) | MAOBNR4A2NR4A1NR4A3SOD1 | |
| SCHEMBL11125159 | 0.85 | MAOB (0.57) | MAOBNR4A2NR4A1NR4A3SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220380402-A1 | 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-12-01 | — | — | US | disclosed |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX, INC. | 2019-11-14 | — | — | US | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | XIAMEN UNIVERSITY (CN) | 2019-01-08 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-01-25 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | XIAMEN UNIVERSITY (CN) | 2017-11-23 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265281-A1 | Organic Compounds and Their Uses | COTTENS SYLVAIN | 2007-11-15 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | MAOB 2808/4885NR4A2 3445/4885NR4A1 3899/4885 |
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | MAOB 1634/4885NR4A2 1528/4885NR4A1 2088/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | MAOB 2122/4885NR4A2 1424/4885NR4A1 3040/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | MAOB 202/4885NR4A2 1081/4885NR4A1 1732/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | MAOB 1020/4885NR4A2 1841/4885NR4A1 2432/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | MAOB 4400/4885NR4A2 2405/4885NR4A1 4244/4885 |
| US-20180022709-A1 | Compositions and Methods for Treating Toxoplasmosis, Cryptosporidiosis, and Other Apicomplexan Protozoan Related Diseases | PNCK, TXK, CILK1 | MAOB 4796/4885NR4A2 2770/4885NR4A1 3063/4885 |
| US-20170334896-A1 | Substituted Heterocyclic Derivative, Preparation Method And Use Thereof | FAAH, NAAA, FAAH2 | MAOB 23/4885NR4A2 3655/4885NR4A1 2870/4885 |
| US-20070265252-A1 | 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE AND THIAZINE DERIVATIVES AS CETP INHIBITORS | CETP, MTTP, CES1 | MAOB 1886/4885NR4A2 542/4885NR4A1 753/4885 |
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | MAOB 597/4885NR4A2 1210/4885NR4A1 2467/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | MAOB 1020/4885NR4A2 1841/4885NR4A1 2432/4885 |
| US-20190345115-A1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | MAPT, PSEN1, APP | MAOB 269/4885NR4A2 4023/4885NR4A1 4317/4885 |
| US-20070265281-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | MAOB 90/4885NR4A2 1408/4885NR4A1 2185/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | MAOB 597/4885NR4A2 1210/4885NR4A1 2467/4885 |
| US-10174015-B2 | Substituted heterocyclic derivative, preparation method and use thereof | DHPS, CYP3A5, CYP3A4 | MAOB 30/4885NR4A2 2308/4885NR4A1 1358/4885 |
| US-20220380402-A1 | 6-HYDRAZINOADENOSINE COMPOUNDS WITH A2A ADENOSINE RECEPTOR AGONIST ACTIVITY | ADORA2A, ADORA1, ADORA3 | MAOB 315/4885NR4A2 498/4885NR4A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.